Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

CJC-1295 (without DAC) and Telmisartan Interaction: Synergistic | Peptide Database

Can you take CJC-1295 (without DAC) with Telmisartan? Synergistic interaction (51% confidence). See pharmacological analysis, organ load, safety flags, and dosing guidance.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Telmisartan

Angiotensin II Receptor Blocker | Cardiac Protection On Cycle

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Telmisartan?

Yes, CJC-1295 (without DAC) and Telmisartan can generally be taken together. CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects.

Is CJC-1295 (without DAC) and Telmisartan safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Telmisartan?

CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Telmisartan?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected topics

Follow this recovery question